retatrutide trial data produces up to 30.3% weight loss in Phase 3 Retatrutide Research Concentration Overview |
Description
2022;377: e068882
The assumptions remain the same as in Equation (1), with the addition of oral bioavailability limiting infant systemic exposure following maternal subcutaneous administration of the drug
The data and code needed to reproduce the analyses can be accessed at References Ilic, M
Together, these data suggested that activating GLP-1R alleviated glycolysis, at least partially by the suppression of PFKFB3-driven glycolysis, and attenuated lactate-mediated histone lactylation, which in turn suppressed the transcription of profibrotic genes in TGF-1 + IL-1-challenged fibroblasts
Wiberg F
Psoriasis (Auckl)
